AOAC INTERNATIONAL Announces New Analytical Test for Lactose in Milk


Experts approve new Official Method for accurately measuring lactose even at very low levels

ROCKVILLE, MARYLAND, USA, September 24, 2019 / — Food safety experts gathered at the 133rd AOAC INTERNATIONAL Annual Meeting and Exposition in Denver, Colorado have adopted a new Official Method of Analysis℠ for measuring low levels of lactose in milk.

Lactose intolerance affects approximately 65 percent of the global human population, although it varies greatly between populations. Approximately 5 percent of northern European and over 90 percent of Southeast Asian populations are affected.

Lactose, the most abundant sugar in dairy products, is normally hydrolyzed during digestion by the enzyme lactase-phlorizin hydrolase. People deficient in this enzyme can experience gastrointestinal symptoms including nausea, cramps, bloating and diarrhea. In commercially manufactured low-lactose and lactose-free dairy products, most of the lactose has already been hydrolyzed into glucose and galactose which are well tolerated. The new method promotes public health by allowing greater precision in measuring remaining lactose.

The new analytical method, “K-LOLAC Enzymatic Low Lactose Assay,” was developed by a team of scientists at Megazyme, headquartered in Bray, Ireland, and was presented to an AOAC Expert Review Panel in a report by R. Ivory, E. Delaney, D. Mangan and B.V. McCleary. The method involves two key steps, namely sample clarification and enzymatic removal of free glucose, followed by spectrophotometric measurement of remaining glucose in the sample before and after incubation with a specific beta-galactosidase. Lactose in the sample is then calculated.

“We wanted to design a lower cost, faster method, where it was possible to run multiple samples at the same time, and that’s what we have developed,” said Barry McCleary, CEO and founder of Megazyme. “A key element of the method being accepted globally is AOAC validation, so we are very gratified that it has now earned First Action status. This is our 11th validated method and we are very committed to the AOAC process.”

The method was adopted as a First Action Official Method of Analysis during a meeting of the AOAC INTERNATIONAL Expert Review Panel for Low-Lactose Methods on September 11, 2019. Official Methods of Analysis of AOAC INTERNATIONAL are microbiological and chemical analysis procedures that have undergone rigorous formal validation by AOAC INTERNATIONAL. After a two-year tracking period, First Action methods are reviewed for approval as Final Action methods, which are published in the "Official Methods of Analysis of AOAC INTERNATIONAL," a globally recognized standards resource for analytical scientists.

The method was evaluated against Standard Method Performance Requirement (SMPR®) 2018.009: which details the requirements for testing mono- and di-saccharides. Foods currently on the market can contain compounds that interfere with testing or can have much lower levels of sugar than was common when previous testing methods were developed prior to 2000.


AOAC INTERNATIONAL is a globally recognized, 501(c)(3), independent, third party, not-for-profit association and voluntary consensus standards developing organization founded in 1884. When analytical needs arise within a community or industry, AOAC INTERNATIONAL is the forum for finding appropriate science-based solutions through the development of microbiological and chemical standards. The AOAC Official Methods of Analysis database is used by food scientists around the world to facilitate public health and safety and to promote trade.

Marida Hines
+1 240-912-1445
email us here

Source: EIN Presswire

Walking to Find A Cure For Mesothelioma: The Pacific Mesothelioma Center Hosts Annual Walk/Hike for Meso!

Grab Your Walking Shoes and Join Us for The Walk/Hike for Mesothelioma Research on Sat, October 26th at The Will Rogers State Park in the Pacific Palisades.

LOS ANGELES, CA, USA, September 24, 2019 / — The Pacific Mesothelioma Center (PMC) a division of the Pacific Heart, Lung & Blood Institute (PHLBI) will hold it's eighth annual Walk/Hike for Meso on October 26th at The Will Rogers State Historic Park in the Pacific Palisades. This year the walk will be hosted by CHiPS star and longtime Pacific Mesothelioma Center supporter Larry Wilcox. With the previous year’s success of over 400 participants and $163,000 raised, The Pacific Mesothelioma Center is setting an ambitious $175,000 goal for the walk this year. The PMC’s mission is to find better treatment options for malignant pleural mesothelioma (MPM), a devastating cancer caused by exposure to asbestos with sadly few treatment options. Mesothelioma affects thousands of people each year a third of whom are veterans. The annual walk raises awareness for mesothelioma and provides financial support for pioneering mesothelioma research.

The Walk for Mesothelioma, presented by Worthington & Caron P.C, is the only annual walk on the West coast held to raise funds for mesothelioma research. Teams, consisting of family members and friends of those who died of mesothelioma, as well as supporting organizations and individual walkers, will gather together on October 26th to raise awareness and funds. The cost of registering for the walk is $45 online and $50 the day of the walk. Create a team, join a team, or register as an individual here:

“We are excited to be hosting the walk at our new venue, The Will Rogers State Park. After last year's Woosley fire burned down The Paramount Ranch, The Walk for Mesothelioma was without a venue for some time. We feel very fortunate that we found this historic park with stunning views for this year's event and we think our walkers will love it as well!" PMC Executive Director Clare Cameron shared.

After the walk, there will be a catered lunch by Lalo’s Catering, musical entertainment, and an opportunity drawing. The opportunity drawing and auction offer great prizes including, exciting experiences, great restaurant packages, gift certificates, jewelry, and much more. All of the proceeds go directly to mesothelioma research.

The Pacific Mesothelioma Center at the Pacific Heart, Lung & Blood Institute is a 501(c) (3) non-profit medical research institute that provides the promise of future treatment breakthroughs by exploring innovative ideas, educating the public on asbestos-related diseases and finding the best treatment options for newly diagnosed patients with MPM.

Clare Cameron
The Pacific Heart, Lung & Blood Institute
email us here
Visit us on social media:

Source: EIN Presswire

ImmunoBiology Limited Announces Intention to Build Partnerships for PnuBioVax™, its Universal Pneumococcal Vaccine

ImmBio's lead universal vaccine is against pneumococcal disease, PnuBioVax™, that is in full clinical development with the completion of a Phase I trial.

Our PnuBioVax™ vaccine can become the leader in control of pneumonia, a global health problem. Our novel approach to vaccine development offers a universal approach to all pneumococcal strains.”

— Dr. Enrique Tabares, CEO

CAMBRIDGE, UNITED KINGDOM, September 24, 2019 / — Following the strategic licensing deal with CNBG, the largest Pharmaceutical Vaccine company in China earlier this year, ImmunoBiology Ltd (“ImmBio”; has announced that it is searching for additional strategic partners to develop and commercialise its PnuBioVax™ universal pneumococcal vaccine. AEC Partners, a leading life-sciences advisory firm head quartered in Paris, has been appointed to support this initiative which is at Phase 2 clinical stage of development.

ImmBio owns long lasting IP for development of protein-based vaccines which can potentially target a universal group of strains for disease. This is a unique approach in the field of pneumococcal disease and a clear differentiator from other pharmaceutical companies with vaccine products that target only a small subset of pre-existing Streptococcus pneumoniae polysaccharide variants or serotypes.

Hilde Depraetere, Acting Executive Director at the European Vaccine Initiative (EVI) said: “We are thrilled with our collaboration with ImmBio in the development of the next generation vaccine, PnuBioVax™. The protein-based vaccine has the potential to address the limitations of current serotype dependent vaccines and provide with a long-lasting solution that would impact the socio-economic burden of the disease in both developed and developing countries”.

PnuBioVax™ is a Phase 2-ready protein vaccine, with good Phase 1 clinical safety and immunogenic data, targeting a broad range of Streptococcus pneumoniae serotypes. In pre-clinical studies, PnuBioVax™ was shown to be immunogenic against all S. pneumoniae strains tested to date regardless of the serotype – evidence of a universal vaccine which, together with low cost of manufacture, will give ImmBio market and clinical dominance when PnuBioVax™ is approved by regulatory authorities.

Prof Jeremy Brown, Professor of Respiratory Infection at UCL and an Honorary Consultant at UCLH and a member of the United Kingdom’s Joint Committee on Vaccines and Immunisation, said “Significant pre-clinical data suggests the PnuBioVax™ vaccine can provide serotype-independent protection, thereby potentially addressing the concerns about serotype replacement with the existing capsular polysaccharide vaccines.”

ImmBio’s lead competitor is Pfizer who has reported sales to date of $30 Bn for its polysaccharide-based Prevnar™ vaccine which targets just 13 of more than 90 S. pneumoniae serotypes that have been identified to date. A more serious problem unfolding is the increasing antibiotic resistance (AMR) and emergence of new serotypes not targeted by current vaccines. Pfizer has recently announced the development of a new Prevnar™ polysaccharide-based vaccine targeting as many as 20 serotypes of the pneumococcal bacteria and Merck is positioning its new polysaccharide-based 15-serotype vaccine (V114) as a Prevnar™ competitor.

ImmBio envisions commercialisation partnerships in different regions that will provide, in each geographical area, with a licence to PnuBioVax™ product rights. In addition to these commercial partnerships, Immbio will also seek financial partners to complement the clinical development funding.

Enrique Tabares, CEO of ImmBio, said “We are really excited with the support and the prospects of building a Global Consortium with key strategic and financial partners. Our PnuBioVax™ vaccine has the potential to become the leader in control of pneumonia, a global health problem facing the young and old. We believe that our novel approach to vaccine development can overtake current technologies in development because it offers a universal approach to all pneumococcal strains, both known and those which are likely to develop through mutation and evolution of the bacteria underlying pneumonia. In addition, a universal pneumococcal vaccine would make a significant contribution to the current global efforts to tackle AMR”

For more information about ImmBio, PnuBioVax™, and partnering opportunities for its pipeline drug candidates, please contact:

Jean-Luc Marsat
AEC Partners
Phone: +32 (0)471 90 51 58


Dr. Enrique Tabares, CEO
Phone: +44 (0)1223 496117


Dr. Bill Mason, Director
Phone: +44 (0)7785 950134

About PnuBioVax
PnuBioVax™ has completed a pre-clinical package and a Phase 1 study demonstrated safety in humans as well as efficient generation of immunity without the use of adjuvants. High anti- PnuBioVax™ titres also correlated with quicker clearance in elderly subjects challenged with pneumococcal bacteria.

About Immunobiology Ltd.
ImmBio is based in Cambridge, UK and is privately funded. ImmBio’s portfolio addresses major unmet healthcare needs in infectious disease.

ImmBio's lead programme is a vaccine against invasive pneumococcal disease, PnuBioVax™, that has recently progressed into full clinical development with the successful completion of a Phase I Clinical trial.

ImmBio was founded based on advances in understanding of the immune system, in particular the key role of the dendritic cell (DC) in the integration of innate and acquired immunity. ImmBio utilises two distinct technology platforms, ImmBioVax™ and ImmunoBodies™ to target antigens to DCs. The lead platform, ImmBioVax, is designed for bacerial vaccines and mimics normal immune responses to a pathogen utilising multi-protein complexes to elicit priming of the immune system.

ImmBio’s unique technologies have the following benefits:
• Induce broad immunity effective against multiple pathogen strains and variants
• Potential universal vaccine technology
• Effective, long-lasting immune responses in diverse human populations
• Emulate normal immune responses to pathogens to optimise the safety profile
• Low cost of goods and a clear regulatory pathway to market

ImmBio’s patent estate covers the products and processes associated with its technologies. The company’s lead ImmBioVax™ programme, PnuBioVax™, targets invasive pneumococcal disease. ImmBio currently have collaborations with many leading research centres, including the co-development of ImmBio's pneumococcal vaccine, PnuBioVax™, with a leading Chinese vaccine organisation, the China National Biotec Group, CNBG.

The company also has other vaccines at early stages of development i.e. for meningitis and tuberculosis, with the potential for a partner to address an even wider range of vaccines.

Bill Mason
Immunobiology Ltd
+44 7785 950134
email us here

Source: EIN Presswire